DSRU Medication Errors course
|DSRU Medication Errors course|
|Date||July 05-06, 2017|
DSRU's Medication Errors course is an interactive course designed to provide delegates with the necessary skills and knowledge required to collect, assess and report medication error information in line with the recommendations from the European Medicines Agency. You will have the opportunity to exchange experience on the new good practice guides on medication errors, increase your awareness of the requirements and discuss operational aspects of the implementation of the guidance.
Practical coaching takes place in small groups where delegates have the opportunity to discuss individual cases, risk management strategies and receive feedback from expert tutors.
History of DSRU
Post-marketing surveillance (PMS) of new drugs is imperative to quantify common adverse drug reactions and to identify rare adverse reactions. The whole ethos of drug safety monitoring or ‘pharmacovigilance’ as it is known today, came into being through the tragedy of thalidomide,
DSRU established in 1980
Formerly known as the Drug Surveillance Research Unit, the Drug Safety Research Unit (DSRU) was founded in 1980 by Professor William Inman, one of the earliest contributors to post marketing surveillance and the person responsible for developing the yellow card system. Although spontaneous reporting systems have many real advantages, he recognised their limitations and as a result Professor Inman established the DSRU and devised a method for the early detection of potential drug hazards known as Prescription-Event Monitoring (PEM), which he based on ‘Event Monitoring’ (Finney D.J. The design and logic of a monitor of drug use. J. Chron. Dis. 1965, 18:77). Initially, having received an initial grant from the Office of the Chief Scientist together with unconditional pledges from the pharmaceutical industry, the DSRU was part of the Faculty of Medicine at the University of Southampton. However in 1986, it was reconstituted as a registered independent charity (No. 327206), changing its name to Drug Safety Research Unit because of the emotive connotation of the word ‘surveillance’.
- Assessment of medication error reports and MedDRA coding
- Practical aspects of implementation in Global, Affiliate, Medical Information and Product Quality teams
- Medication error signal detection and data presentation in PBRERs
- Risk management strategies tailored to medication errors
- Pharmaceutical industry personnel from areas including pharmacovigilance, clinical research, medical affairs, medical writing, regulatory affairs and medical information
- Staff from regulatory authorities